
    
      This study will be conducted in two stages:

      At 10 months age, half of the subjects will receive a dose of plain meningococcal AC and PRP
      polysaccharide (PS) vaccine at 10 months age.

      At 15 to 18 months age (DTP booster phase), all subjects will receive a booster dose of
      Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hib2.5.
    
  